Mayo Clinic Laboratory and Pathology Research Roundup: February 27

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.

Both targeted therapies and immunotherapies provide benefit in resected Stage III melanoma. We hypothesized that the combination of targeted and immunotherapy given prior to therapeutic lymph node dissection (TLND) would be tolerable and drive robust pathologic responses. 

Read more.

Published to PubMed This Week

Sarah Jarvis

Sarah Jarvis is a Senior Marketing Specialist at Mayo Clinic Laboratories. She supports marketing strategies for paid media.